Arbutus Biopharma Corp (ABUS)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch ABUS
See up to 3 months of ABUS. The 7-day demo opens the 1M and 3M ranges and puts ABUS on your watchlist.
Start 7-day demoLatest ABUS insider trades
Robert A. Beardsley - DirectorDerivative$90K- Tuan Nguyen - OfficerDerivative$240K
- Roger Sawhney - DirectorDerivative
About Arbutus Biopharma Corp (ABUS)
The SEC lists Arbutus Biopharma Corp under CIK 0001447028, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
ABUS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Option exercise | 16 | 1,365,260 | |
| Tax withholding / forfeiture | 4 | 488,729 | |
| Derivative transaction | 5 | 9,075,209 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ABUS insider transactions (Form 4)
3214 Form 4 filings on record, the earliest from Aug 4, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Robert A. Beardsley - Director | Derivative | Common Shares | 17,948 footnote F1 | $5.00 | $90K | |
| ||||||
| Tuan Nguyen - Officer | Derivative | Common Shares | 48,081 footnote F1 | $5.00 | $240K | |
| ||||||
| Roger Sawhney - Director | Derivative | Common Shares | 17,142 footnote F1 | $5.00 | $86K | |
| ||||||
| Lindsay Androski - Officer | Derivative | Common Shares | 24,655 footnote F1 | $5.00 | $123K | |
| ||||||
| Roivant Sciences Ltd. - Director | Derivative | Common Shares | 8,967,383 | $5.00 | $44.84M | |
| Lindsay Androski - Officer | Option exercise | Common Shares | 116,408 | $3.20 | $373K | |
| Lindsay Androski - Officer | Option exercise | Common Shares | 10,456 | $4.39 | $46K | |
| Lindsay Androski - Officer | Tax withholding / forfeiture | Common Shares | 82,527 | $5.07 | $418K | |
| Lindsay Androski - Officer | Option exercise | Stock Option (Right to Buy) | 116,408 | $0.00 | - | |
| Lindsay Androski - Officer | Option exercise | Stock Option (Right to Buy) | 10,456 | $0.00 | - | |
| Tuan Nguyen - Officer | Option exercise | Common Shares | 27,475 | $4.39 | $121K | |
| Tuan Nguyen - Officer | Option exercise | Common Shares | 265,625 | $3.49 | $927K | |
| Tuan Nguyen - Officer | Tax withholding / forfeiture | Common Shares | 206,637 | $5.07 | $1.05M | |
| Tuan Nguyen - Officer | Option exercise | Stock Option (Right to Buy) | 265,625 | $0.00 | - | |
| Tuan Nguyen - Officer | Option exercise | Stock Option (Right to Buy) | 27,475 | $0.00 | - | |
| Roger Sawhney - Director | Option exercise | Common Shares | 52,533 | $3.34 | $175K | |
| Roger Sawhney - Director | Option exercise | Common Shares | 78,800 | $4.24 | $334K | |
| Roger Sawhney - Director | Tax withholding / forfeiture | Common Shares | 100,508 | $5.07 | $510K | |
| Roger Sawhney - Director | Option exercise | Stock Option (Right to Buy) | 52,533 | $0.00 | - | |
| Roger Sawhney - Director | Option exercise | Stock Option (Right to Buy) | 78,800 | $0.00 | - | |
| Robert A. Beardsley - Director | Option exercise | Common Shares | 52,533 | $3.20 | $168K | |
| Robert A. Beardsley - Director | Option exercise | Common Shares | 78,800 | $4.24 | $334K | |
| Robert A. Beardsley - Director | Tax withholding / forfeiture | Common Shares | 99,057 | $5.07 | $502K | |
| Robert A. Beardsley - Director | Option exercise | Stock Option (Right to Buy) | 52,533 | $0.00 | - | |
| Robert A. Beardsley - Director | Option exercise | Stock Option (Right to Buy) | 78,800 | $0.00 | - | |
| Roger Sawhney - Director | Grant or award | Stock Option (Right to Buy) | 78,800 | $0.00 | - | |
| Robert A. Beardsley - Director | Grant or award | Stock Option (Right to Buy) | 78,800 | $0.00 | - | |
| Tuan Nguyen - Officer | Grant or award | Common Shares | 73,500 footnote F1 | $0.00 | - | |
| Tuan Nguyen - Officer | Grant or award | Stock Option (Right to Buy) | 188,400 | $0.00 | - | |
| ||||||
| Lindsay Androski - Officer | Grant or award | Common Shares | 28,000 footnote F1 | $0.00 | - | |
| Lindsay Androski - Officer | Grant or award | Stock Option (Right to Buy) | 71,700 | $0.00 | - | |
| ||||||
| Roger Sawhney - Director | Grant or award | Stock Option (Right to Buy) | 157,600 | $0.00 | - | |
Item 8.01, 9.01
Item 2.02, 9.01
Item 1.02, 5.02, 8.01, 9.01
Item 5.02, 5.07, 9.01
ABUS insider trading FAQ
What is the latest insider trade for ABUS?
Arbutus Biopharma Corp (ABUS) had 9 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for ABUS runs to 14 Form 4 filings, the earliest from 2025-08-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ABUS stock?
No insider purchases of ABUS were filed in the last 90 days.
How many insiders are selling ABUS stock?
No insider sales of ABUS were filed in the last 90 days.
Where can I see ABUS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ABUS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Robert A. Beardsley view on EDGAR
- - Tuan Nguyen view on EDGAR
- - Roger Sawhney view on EDGAR
- - Lindsay Androski view on EDGAR
- - Roivant Sciences Ltd. view on EDGAR
- - Lindsay Androski view on EDGAR
- - Tuan Nguyen view on EDGAR
- - Roger Sawhney view on EDGAR
- - Robert A. Beardsley view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ABUS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ABUS with a 7-day demo
- ABUS on your watchlist
- Every ABUS Form 4 filing on record
- Up to 3 months of ABUS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
